The only approved potentiator drug for gating mutations, VX-770, provides significant, albeit partial, restoration of the channel function for the most common gating mutant, G551D-CFTR, while partially inhibits the long-term lung function decay. Several rare gating mutations are marginally responsive to the VX-770 activation but, based on published and preliminary data, we posit that the […]
The only approved potentiator drug for gating mutations, VX-770, provides significant, albeit partial, restoration of the channel function for the most common gating mutant, G551D-CFTR, while partially inhibits the long-term lung function decay. Several rare gating mutations are marginally responsive to the VX-770 activation but, based on published and preliminary data, we posit that the […]
Stefano Manfredini is Professor of Pharmaceutical chemistry and toxicology Director of the B. Sci. in Pharmacy of the University of Ferrara
Stefano Manfredini è Professore Ordinario di Chimica farmaceutica e Coordinatore del Corso di Laurea in Farmacia dell’Università di Ferrara
Paolo Pinton is Professor of General Pathology and Coordinator of the PhD Program in Biomedical Sciences and Biotechnology of the University of Ferrara Dept. of Medical SciencesSection of Experimental Medicine – University of Ferrara Biographical sketch EDUCATION1996: Biological Sciences Degree summa cum laude (University of Padova)1998: National Board (University of Padova)2002: Ph.D. in Molecular and Cellular Biology and […]
Paolo Pinton è Professore Ordinario di Patologia Generale e Coordinatore del Programma di Dottorato di Ricerca in Scienze Biomediche e Biotecnologie Dipartimento di Scienze MedicheSezione di Medicina Sperimentale – Università di Ferrara Biographical sketch EDUCATION1996: Biological Sciences Degree summa cum laude (University of Padova)1998: National Board (University of Padova)2002: Ph.D. in Molecular and Cellular Biology and […]
I mitocondri come elementi centrali nella risposta infiammatoria polmonare in fibrosi cistica Un farmaco o un trattamento ideale in fibrosi cistica (FC) dovrebbe essere una molecola che genera condizioni favorevoli per ripristinare o potenziare la residua funzionalità del canale regolatore della conduttanza transmembrana della fibrosi cistica (CFTR) mutato, interrompendo inoltre il ciclo vizioso che sostiene […]
Adriana Chilin graduated in Pharmaceutical Chemistry and Technology at the University of Padua on December 16, 1983 with a grade of 110/110 cum laude. In 1984 she worked in the chemical R&D laboratories of Glaxo Italia in Verona, IT. She then obtained the PhD in Pharmaceutical Sciences in 1989 at the University of Padua, IT. […]
Adriana Chilin si è laureata in Chimica e Tecnologia Farmaceutiche presso l’Università degli Studi di Padova il 16 dicembre 1983 con la votazione di 110/110 e lode. Nel 1984 ha lavorato nei laboratori di R&D Chimica di Glaxo Italia a Verona. Ha poi conseguito il titolo di dottore di ricerca in Scienze Farmaceutiche nel 1989 […]
Since 1985 I have been working in pediatrics, initially following infectious diseases. In 1988 I begun to work in cystic fibrosis (CF), focusing my attention to respiratory aspects. Since 1991 I have been studying also gastroenterological aspects, in particular liver and pancreatic issues of both cystic fibrosis and non-cystic fibrosis patients. In the same year […]